Paris, Ile-de-France, France Calmedica appeared to be the Corporate Investor, which was created in 2013. The main department of described Corporate Investor is located in the Paris. The venture was found in Europe in France.
Among the most popular portfolio startups of the fund, we may highlight Capricor Therapeutics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Biotechnology, Therapeutics.
Deals in the range of 1 - 5 millions dollars are the general things for fund. The fund is constantly included in less than 2 investment rounds annually. The top amount of exits for fund were in 2008. The top activity for fund was in 2009.
The current fund was established by Alexis Hernot.
The typical case for the fund is to invest in rounds with 2 participants. The meaningful sponsors for the fund in investment in the same round are Beechwood Ventures. In the next rounds fund is usually obtained by Broadview Ventures.
| Fund Name | Location |
| Aihuishou | China, Hainan, Yangpu |
| Argo Capital Partners | - |
| Baroda Ventures | Beverly Hills, California, United States |
| Chinar Capital | - |
| ClubRACC | - |
| Eastern Asia Technology | - |
| Premier Prophet Assets Management | China, Shanghai |
| Shinetech Software | - |
| Sigefi Ventures Gestion | France, Lyon, Rhone-Alpes |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data 